DecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck
May 03 2024 - 6:00AM
Business Wire
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving
health through innovative tests that guide patient care, today
announced that new data supporting the utility of its
DecisionDx-SCC test in patients with high-risk cutaneous squamous
cell carcinoma (SCC) tumors located on the head and neck (H&N)
will be shared at the 56th American College of Mohs Surgery (ACMS)
Annual Meeting, being held May 2-5 in Phoenix.
“Mohs surgery is commonly used to remove high-risk SCC tumors
located on a patient’s head or neck and is the best method to
ensure complete removal of the tumor,” said Sherrif Ibrahim, M.D.,
Ph.D., lead study author and board-certified Mohs micrographic
surgeon and dermatologist at Rochester Dermatologic Surgery in
Victor, New York. “In most cases, once a tumor is removed
completely, the patient is in the clear. However, aggressive SCC
tumors may still return in the same location from which they were
removed or worse, spread to other parts of the body, posing a very
serious health risk to patients.
“The data being presented at ACMS show the power of
DecisionDx-SCC to identify these high-risk patients, enabling more
risk-appropriate surveillance or adjuvant treatments to help reduce
the patient’s risk of these events occurring.”
Details regarding Castle’s poster at ACMS are included
below:
- Title: Addition of the 40-gene expression profile
(40-GEP) test in risk assessment improves prognostic accuracy and
risk stratification for high-risk cutaneous squamous cell carcinoma
(HR-cSCC) of the head and neck successfully treated with Mohs
micrographic surgery (MMS)
- Poster Number: Poster 21
- First and Presenting Author: Sherrif Ibrahim, M.D.,
Ph.D.
- Location: Valley of the Sun Ballroom foyer (2nd floor),
Sheraton Phoenix Downtown
- Summary: Despite reported definitive, clear tumor
margins, 5-8% of patients with high-risk SCC treated with Mohs
surgery will still develop metastasis. This study included 417
patients who received definitive Mohs surgery to remove high-risk
SCC tumors of the H&N with reported clear margins.
DecisionDx-SCC testing of the tumor tissue before removal
significantly increased the prediction accuracy of metastatic
events, when used alone and when combined with National
Comprehensive Cancer Network (NCCN) guidelines, Brigham and Women’s
Hospital (BWH) staging or American Joint Committee on Cancer
Staging Manual, 8th Edition (AJCC8) staging, to better guide
risk-aligned patient care decisions regarding metastatic
surveillance or the use of adjuvant treatments like radiation.
Presenting authors will be available to answer questions
regarding their posters on Saturday, May 4, from 12-1 p.m. Mountain
Standard Time. Abstracts will also be in ACMS' CME & Abstract
Book and available for online viewing via the Planstone abstract
site.
About DecisionDx-SCC
DecisionDx-SCC is a 40-gene expression profile test that uses an
individual patient’s tumor biology to predict individual risk of
cutaneous squamous cell carcinoma metastasis for patients with one
or more risk factors. The test result, in which patients are
stratified into a Class 1 (low), Class 2A (higher) or Class 2B
(highest) risk category, predicts individual metastatic risk to
inform risk-appropriate management. Peer-reviewed publications have
demonstrated that DecisionDx-SCC is an independent predictor of
metastatic risk and that integrating DecisionDx-SCC with current
prognostic methods can add positive predictive value to clinician
decisions regarding staging and management.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics
company improving health through innovative tests that guide
patient care. The Company aims to transform disease management by
keeping people first: patients, clinicians, employees and
investors.
Castle’s current portfolio consists of tests for skin cancers,
Barrett’s esophagus, mental health conditions and uveal melanoma.
Additionally, the Company has active research and development
programs for tests in other diseases with high clinical need,
including its test in development to help guide systemic therapy
selection for patients with moderate-to-severe atopic dermatitis,
psoriasis and related conditions. To learn more, please visit
www.CastleBiosciences.com and connect with us on LinkedIn,
Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath
Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM,
DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle
Biosciences, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, which are subject to the “safe harbor” created by those
sections. These forward-looking statements include, but are not
limited to, statements concerning: the ability of the
DecisionDx-SCC test to identify high-risk patients and
significantly increase the prediction accuracy of metastatic
events, to better guide risk-aligned patient care decisions
regarding metastatic surveillance or the use of adjuvant treatments
like radiation. The words “can,” “potential” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. We may not actually achieve the plans,
intentions or expectations disclosed in our forward-looking
statements, and you should not place undue reliance on our
forward-looking statements. Actual results or events could differ
materially from the plans, intentions and expectations disclosed in
the forward-looking statements that we make. These forward-looking
statements involve risks and uncertainties that could cause our
actual results to differ materially from those in the
forward-looking statements, including, without limitation:
subsequent study or trial results and findings may contradict
earlier study or trial results and findings or may not support the
recommendations and guidelines presented in this report, including
with respect to the discussion of DecisionDx-SCC in this press
release; actual application of our tests may not provide the
aforementioned benefits to patients; and the risks set forth under
the heading “Risk Factors” in our Annual Report on Form 10-K for
the year ended December 31, 2023, and in our other filings with the
SEC. The forward-looking statements are applicable only as of the
date on which they are made, and we do not assume any obligation to
update any forward-looking statements, except as may be required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240503767002/en/
Investor Contact: Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact: Allison Marshall
amarshall@castlebiosciences.com
Castle Biosciences (NASDAQ:CSTL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Castle Biosciences (NASDAQ:CSTL)
Historical Stock Chart
From Sep 2023 to Sep 2024